While additional studies to correlate intratumoral TCN2 expression with plasma APO-TCN2 levels are necessary, these data suggest that circulating protein measurements (through liquid biopsy) could act as a surrogate for tumoral assessments in both local and advanced OSA. This evidence concerns the gene TCN2 and obstructive sleep apnea syndrome.